Title
Category
Credits
Event date
Cost
  • LivDerm
  • TME
  • 1.75 AAPA Category I CME
  • 1.75 AMA PRA Category 1 Credit
  • 1.75 ANCC
  • 1.75 Participation
$0.00
Pediatric patients with melanin-rich skin, or skin of color (SOC), can be disproportionately affected by numerous dermatologic conditions. Patients can be more susceptible or have a greater disease burden, especially with conditions such as acne, atopic dermatitis, psoriasis, pigmentary disorders, and hair disorders.
  • LivDerm
  • TME
  • 0.25 AMA PRA Category 1 Credit
  • 0.25 ANCC
  • 0.25 Participation
$0.00
Timely and adequate treatment of atopic dermatitis (AD) is essential for helping to promote better long-term outcomes and quality of life and may help prevent the development of other atopic conditions.
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
Lowering LDL-C effectively and safely is paramount to prevent and lower the risk of recurrent ASCVD events. Even with the advances in LDL-C lowering therapy, LDL-C goal achievement is low, and clinical inertia and patient non-adherence are major factors for continued ASCVD residual risk. The landscape of LDL-C lowering therapy is rapidly evolving, with several new and emerging agents that may help address these gaps.
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
Iron deficiency anemia (IDA) is a common condition in patients with non–dialysis-dependent chronic kidney disease (NDD-CKD) that can affect quality of life and lead to suboptimal outcomes. Despite the impacts of IDA in NDD-CKD patients, its screening, diagnosis, and treatment remains challenging. Recent trials and evidence has shown that i.v. iron supplementation for the treatment of IDA might be beneficial in this setting, and during this webcast,, experts will discuss important advances and considerations about the screening, diagnosis, and treatment of IDA in patients with NDD-CKD.
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
Iron deficiency anemia (IDA) is the most common cause of anemia in patients with non–dialysis-dependent chronic kidney disease (NDD-CKD) and addressing this condition is important in the overall management of these patients. During this webcast, expert faculty utilize challenging cases to discuss important clinical pearls about the screening, diagnosis and treatment of IDA in NDD-CKD.This activity is part of the IDA in NDD-CKD Digital Education Hub.
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
Expert faculty developed three challenging cases that illustrate practical points about the current challenges of optimizing LDL-C lowering therapy, as well as how to optimize treatment with statin and non-statin therapies. In addition, the cases serve to offer clinical pearls on how the newer therapies fit into the treatment landscape and inform patient selection. During the webcast, expert faculty engage in interactive discussions to offer additional perspectives and clinical pearls.
  • CMHC
  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit
  • 0.75 ANCC
  • 0.75 Participation
$0.00
Atherosclerotic cardiovascular disease (ASCVD) events are among the leading causes of death in women in the US and globally. Even with advances in LDL-C (low-density lipoprotein cholesterol) lowering therapy, LDL-C goal achievement in high-risk women is lower than that in men, with clinical inertia, statin intolerance, and non-adherence being major factors for continued ASCVD residual risk.
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
Expert faculty developed challenging cases to illustrate practical points in the optimization of LDL-C therapy post-MI, including, but not limited to the points illustrated below. At the end of each case, faculty engage in discussions to offer clinical pearls and expert insights on the cases.
  • CMHC
  • 18.50 ABIM MOC and AMA PRA Category 1 Credit
  • 18.50 ACPE Pharmacy
  • 18.50 AMA PRA Category 1 Credit
  • 18.50 ANCC
  • 18.50 CDE
  • 18.50 Participation
$0.00
Hundreds of practitioners gathered in Boston in October 2022 for the annual conference from Cardiometabolic Health Congress (CMHC). In the past 17 years, this medical conference has grown to be the biggest and most-anticipated event in evidence-based education for the diagnosis, treatment, and management of cardiometabolic diseases and risk factors. The On-Demand program includes all recordings from the general sessions of the live meeting; CME Symposia are posted as separate activities within the CMHC Educational Platform.
  • TME
  • 1.25 AMA PRA Category 1 Credit
  • 1.25 ANCC
  • 1.25 Participation
$0.00
Rett Syndrome is one of the most frequent causes of mental disability in females, with an estimated prevalence of 1 in 10,000 under the age of 12. It is characterized by normal early growth and development followed by a slowing of development, loss of purposeful use of the hands, distinctive hand movements, slowed brain and head growth, problems with walking, seizures, and intellectual disability.

Pages